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MutagenesisThe glycoprotein of lymphocytic choriomeningitis virus (LCMV) contains nine potential N-linked
glycosylation sites. We investigated the function of these N-glycosylations by using alanine-scanning
mutagenesis. All the available sites were occupied on GP1 and two of three on GP2. N-linked glycanmutations
at positions 87 and 97 on GP1 resulted in reduction of expression and absence of cleavage and were necessary
for downstream functions, as conﬁrmed by the loss of GP-mediated fusion activity with T87A and S97A
mutants. In contrast, T234A and E379N/A381T mutants impaired GP-mediated cell fusion without altered
expression or processing. Infectivity via virus-like particles required glycans and a cleaved glycoprotein.
Glycosylation at the ﬁrst site within GP2, not normally utilized by LCMV, exhibited increased VLP infectivity.
We also conﬁrmed the role of the N-linked glycan at position 173 in the masking of the neutralizing epitope
GP-1D. Taken together, our results indicated a strong relationship between fusion and infectivity.ne, Departments of Molecular
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TheArenaviridaeareenvelopedRNAvirusesgenerally associatedwith
rodent-transmitted disease in humans, where they can induce both
neurological and systemic disease. The diseases induced by each of these
viruses range frommild infections to severe life-threatening acute febrile
illnesses in which shock is a frequent feature. Headache, lethargy, fever,
myalgia, abdominal pain, and conjunctivitis are early common signs in all
of these infections. Encephalopathic signs with tremor, seizures, and
altered consciousness may occur in the South American hemorrhagic
fevers and severe Lassa fever. The spectrum of disease in humans
includes aseptic to acute meningitis, self-limited neurologic syndrome,
pneumonia, heart damage, kidney damage, and hemorrhagic fevers
(McCormick and Fisher-Hoch, 2002; Peters and Zaki, 2002). The high
degree of genetic variation among geographic and temporal isolates of
the same arenavirus species supports the concept of continued
emergence of new pathogens (Sevilla and de la Torre, 2006). This was
sustained by a recent outbreak of ﬁve cases of undiagnosed hemorrhagic
fever, four of them fatal, in South Africa in 2008. A novel arenavirus was
identiﬁed and classiﬁed as a new species, designated Lujo virus, in the
genus Arenavirus (Briese et al., 2009; Paweska et al., 2009).The prototypic arenavirus, lymphocytic choriomeningitis virus
(LCMV), is found worldwide. The house mouse, Mus musculus, is the
natural reservoir, but LCMV can also infect other wild, pet and
laboratory rodents, and notably the index case in a recent cluster of
transplantation-associated deaths was traced to a pet hamster
(Amman et al., 2007; Deibel et al., 1975; Fischer et al., 2006). Humans
can be infected through exposure to infected rodent excreta. Person-
to-person transmission is rare but has occurred through maternal–
fetal transmission and solid organ transplantation (Barton, 2006).
LCMV infection in humans can be asymptomatic or cause a spectrum
of illness ranging from isolated fever to meningitis and encephalitis.
Overall, the case fatality is b1%. Fetal infections can result in
congenital abnormalities or death (Barton and Mets, 2001).
Virions of LCMV are composed of a nucleocapsid surrounded by a
lipid bilayer, presenting spikes of glycoproteins (GP) (Neuman et al.,
2005). The initial step in LCMV infection involves interaction of GP
with the cellular receptor of target cells (Cao et al., 1998). After
internalization of the virions within vesicles, LCMV GP mediates
fusion of the viral and cellular membranes, resulting in the delivery
of the nucleocapsids into the cytoplasm (Borrow and Oldstone,
1994; Di Simone and Buchmeier, 1995; Di Simone et al., 1994;
Klewitz et al., 2007; York et al., 2008).
The 498-amino-acid glycoprotein complex (GPC) of LCMV consists
of three domains (Fig. 1A). The stable signal peptide (SSP), GPC residues
1–58, is co-translationally cleaved by a signal peptidase. The full-length
GPC is cleaved into GP1 (residues 59–265) and GP2 (residues 266–498)
by the cellular protease SK-1/S1P (Beyer et al., 2003) and forms a spike
complex (Wright et al., 1990). GP1 is heavily glycosylated with 6
224 C.J. Bonhomme et al. / Virology 409 (2011) 223–233predicted N-glycosylation sites for LCMV Armstrong clone 5 (Arm-5)
and 5 predicted N-glycosylation sites for the clone 4 (Arm-4) (Wright
et al., 1989). GP1 contains the receptor binding site and antibody
neutralization sites and is non-covalently associated with GP2 (Burnsand Buchmeier, 1991). GP2 contains 3 predicted N-glycosylation sites
and a transmembrane region that anchors the GP complex in the lipid
bilayer of the cell membrane and virus envelope (Agnihothram et al.,
2009; Burns and Buchmeier, 1991).
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encoded by members of the Arenaviridae genus revealed that 4 N-
glycosylation sites on GP2 are conserved in all members except the
Old World LCMV and Dandenong lacking the second N-glycosylation
site and the New World Latino lacking the third. On the contrary,
there is high diversity in both the number and position of N-
glycosylation sites on GP1. However, a similar pattern appears for the
Old World arenaviruses, where LCMV and Dandenong lack the third
N-glycosylation site compared to the other Old World arenaviruses
(Fig. 1B). In order to test the effect of glycan removal on a
representative member of the arenavirus genus, we decided to use
LCMV to reintroduce the conserved glycosylation site on GP2 present
in all the other arenaviruses as well as the conserved glycosylation site
in GP1 for the Old World arenaviruses.
N-linked glycosylations are important for both protein folding and
function (Helenius and Aebi, 2001; Wyss and Wagner, 1996).
Moreover, Wright et al. (1989) demonstrated that N-linked glycosy-
lations play a role in the formation of neutralizing epitopes for LCMV.
Epitope GP-1D is a conformational epitope and is dependent on the
presence of N-linked glycosylation (Wright et al., 1989). It is also the
case for other viruses like inﬂuenza C (Sugawara et al., 1988) and
human immunodeﬁciency virus (Quinones-Kochs et al., 2002).
Dramatic phenotypic differences among closely-related LCMV
isolates indicate that few amino acid replacements in LCMV proteins
could sufﬁce to produce important alterations in viral biological
properties (Sevilla and de la Torre, 2006). In the present study, we
determined the use of various N-glycosylation sites in GPC individ-
ually and assessed their roles in protein folding, intracellular
trafﬁcking and fusion of the LCMV glycoprotein with the cell
membrane. Furthermore, we generated virus-like particles (VLP) to
evaluate the role of N-glycans in virus infectivity. Our results indicate
that these N-glycosylation sites selectively affected a variety of
downstream GP functions, including expression, cleavage, pH-
dependent fusion and formation of infectious particles. Finally, we
demonstrate that antibody recognition of the epitope GP-1D is
blocked by the presence of an N-glycosylation site at position 173
and the epitope is restored by mutation of this N-glycosylation site.
Results
Utilization of potential N-linked glycosylation sites on the LCMV
glycoprotein
Nine potential sites for the attachment of N-linked oligosacchar-
ides are predicted on LCMV Arm-5 glycoprotein. Two more N-
glycosylation sites were added according to sequence alignment with
the Old World arenavirus Lassa strain GA391 (Nigeria) (Figs. 1A and
B). These sites are characterized by Asn-X-Ser/Thr motifs. To
determine the use of each site for the attachment of oligosaccharide,
we mutated the 9 N-glycosylation sites by replacing the serine (S) or
threonine (T) residue in the N-glycosylation motif with alanine (A).
Moreover, we inserted twoN-glycosylation sites present in Lassa virus
within the LCMV glycoprotein (G104N and E379N/A381T). These
mutants were expressed in both HEK 293T and DBT cells and cell
extracts were analyzed by Western blot. Membranes were probedFig. 1. LCMV GPC. (A) LCMV glycoprotein overview. The signal peptide SSP (aa 1–58), the
(aa 266–498) containing the transmembrane anchor (aa 439–456, black) are shown. Nine
T173A, T234A, S373A, S398A and T403A). Creation of N-glycosylation sites from Lassa viru
sequences. Sequence alignment of arenavirus GP1 and GP2 was done using CLC Sequence Vi
8 viruses in the square represent Old World arenaviruses, while the lower part represents Ne
Lassa virus (LASV), X52400; Ippy virus (IPPYV), DQ328877; Mobala virus (MOBV), AY34239
virus (DANV), EU136038; lymphocytic choriomeningitis virus (LCMV), AY847350; Lujo viru
Pichinde virus (PICV), NC_006447, Parana virus (PARV), AF512829; Flexal virus (FLEV), AF5
(MACV), NC_005078; Junin virus (JUNV), D10072; Tacaribe virus (TCRV), NC_004293; Chap
NC_005077; Amapari virus (AMAV), AF512834; Cupixi virus (CPXV), AF512832; Skinner Tank
(CATV), DQ865245; Tamiami virus (TAMV), AF512828; Bear Canyon virus (BCNV), AF5128with monoclonal antibody 83.6, which recognizes residues 370–378
of GP2 (Weber and Buchmeier, 1988). This allowed us to detect both
unprocessed GPC and cleaved GP2 at 75 kDa and 35 kDa, respectively
(Fig. 2A). LCMVN-glycosylation site mutants on LCMVGPC resulted in
an increased electrophoretic mobility corresponding to a decrease of
approximately 3 kDa compared to wild type (wt) glycoprotein,
indicating that the mutated glycoproteins lacked an oligosaccharide.
This pattern was observed with all N-glycosylation site mutations on
GP1. However, only the predicted N-glycosylation sites at positions
398 and 403 in GP2 seemed to be used. Indeed, the ﬁrst predicted N-
glycosylation site of GP2 at position 373 did not exhibit an increased
electrophoretic mobility. On the contrary, inserted N-glycosylation
sites from Lassa virus in LCMV exhibited a gain of molecular mass
(Fig. 2A). In conclusion, these data suggest that 8/9 native N-
glycosylation sites were used. At the same time, the data indicated
that the LCMV glycoprotein was able to use non-native N-glycosyl-
ation sites inserted in GP1 and GP2.
N-glycosylation site mutations T87A, S97A and G104N impair GPC
expression and processing
To determine the role of the N-linked glycans in GPC expression
and processing, we transfected HEK 293T cells with mutated N-
glycosylation site constructs and quantiﬁed the total expression of
GPC/GP2 by ﬂow cytometry (Fig. 2B). Cleavage into GP1/GP2 was
analyzed with corresponding cell lysates by Western blot. The
presence of the GP2 epitope in both the unprocessed GPC and the
cleaved GP2 allowed us to compare the efﬁciency of the GPC cleavage
into GP1 and GP2 (Fig. 2C). The results obtained from the
quantiﬁcation are summarized in Table 1. Most mutations did not
impair GPC expression and cleavage with the exception of the T87A,
S97A and less drastically G104N. These three mutants were impaired
in expression of GPC and resulted in nearly undetectable levels of
cleaved GP2 (Figs. 2A, B and C). These results highlight the functional
importance at positions 87, 97 and 104 located in GP1 for expression
and processing. Mutants at positions 116, 126, 173, 234 and 403 did
not affect the cleavage compared to the wt. On the contrary,
mutations S373A, E379N/A381T and S398A in GP2 improved the
cleavage of the LCMV glycoprotein. To assess the correlation between
cleavage and GP expression, the percentage of expression was
measured by ﬂow cytometry and the percentage of cleavage were
plotted for all mutants (Fig. 2D). We observed a correlation between
GPC expression and cleavage, with the cleavage being impaired when
the expression fell below 75% compared to the wt.
N-glycosylation site mutations did not affect cell surface localization
We examined the effects of N-glycosylation site mutations on the
transport of theGPcomplex to the cell surface,whereviral assembly and
buddingoccur. Cellswere transfectedwith the differentGPmutants and
cell surface expression was assessed by immunoﬂuorescence and by
ﬂow cytometry on non-permeabilized cells with anti-GP2 antibody.
Expression levels, quantiﬁed by ﬂow cytometry, were normalized with
respect to the wt. Representative results of immunoﬂuorescence are
shown in Fig. 3A, whereas a summary of the quantiﬁcation is shown inprecursor glycoprotein GPC (aa 59–498) and the subunits GP1 (aa 59–265) and GP2
N-glycosylation site substitution mutants were obtained (T87A, S97A, S116A, T126A,
s (G104N and E379N/A381T) is represented in grey. (B) Alignment of arenavirus GP
ewer software. Colored amino acid represented the predicted N-glycosylation sites. The
wWorld arenaviruses. Arenavirus abbreviations and accession numbers are as follows:
0; Mopeia virus (MOPV), DQ328874; Morogoro virus (MORV), EU914103; Dandenong
s (LUJV), FJ952384; Pirital virus (PIRV), AF277659; Allpahuayo virus (ALLV), AY012687;
12831; Oliveros virus (OLVV), U34248; Latino virus (LATV), AF512830; Machupo virus
are virus (CHAV), EU260463; Sabia virus (SABV), NC_006317; Guanarito virus (GTOV),
virus (SKTV), EU123328;Whitewater Arroyo virus (WWAV), AF228063; Catarina virus
33.
Fig. 2. Expression and processing of N-glycosylation mutants. (A)Western blot analysis. At 48 h post-transfection, HEK 293T cell lysates were separated by SDS–PAGE, transferred to
nitrocellulose membranes and probed with a GP2-speciﬁc antibody, 83.6. Shifts in expected size of GPC and GP2, represented by lines next to each panel, indicate the use of the
mutated N-glycosylation site. (B) Total expression of N-glycosylation site mutants measured by ﬂow cytometry. The expression for each mutated N-glycosylation sites is expressed
as a percentage of wt expression. Error bars indicate standard errors of the means. (C) Percentage of cleaved GPC into GP2. (D) Correlation between percent expression and percent
cleavage. Percent expression versus percent cleavage was plotted for all N-glycosylation site mutants. The transversal dot line represents the cutoff and shows no cleavage when the
percent expression is b75%. Error bars indicate standard errors of the means.
226 C.J. Bonhomme et al. / Virology 409 (2011) 223–233Fig. 3B and Table 1. All mutations exhibited similar or increased surface
expression. It was particularly true for the mutation S373A and the N-
glycosylation site mutation T126A where we observed an increase of
1.5-fold. No correlation between the surface expression and the
cleavage was observed (Fig. 3C). Since cognate GPC cleavage was not
required for cell surface localization as conﬁrmed with the defective
mutants T87A and S97A, N-glycosylations appeared to not be involved
in the GPC transport to the cell surface.
N-glycosylation site mutations T234A and E379N/A381T impair
GP-mediated cell fusion
In order to investigate the possibility that N-glycosylation site
mutations affected viral fusion, we tested each mutant in a cell
fusion assay. N-glycosylation site mutants were transfected into DBT
cells and the ability to promote syncytium formation was assessed.A representative example of the fusion assay is shown in Fig. 4A,
with a summary of the results in Fig. 4B and Table 1. No GP-
mediated fusion was observed for T87A and S97A mutants and N-
glycosylation site mutants G104N, E379N/A381T and T234A exhib-
ited a ≥50% decrease in GP-mediated fusion compared to the wt. All
other mutants exhibited GP-mediated fusion efﬁciency similar to
the wt. The results of T87A, S97A and G104N mutants suggest that
GP-mediated fusion at pH 5 required prior GPC cleavage. However,
deletion of glycan at position 234 or addition of glycan at position
379/381, in GP2, impaired the GP-mediated cell fusion capacity. To
test whether the effect of N-glycosylation site mutations on fusion
events correlated with cleavage processing, fusion index versus
percentage of cleavage was plotted for all N-glycosylation site
mutants (Fig. 4C). We observed fusion indices less than 0.2 when
the cleavage fell below 75%, yet cleavage alone did not guarantee
GP-mediated fusion.
Table 1
Biochemical properties affected by N-glycosylation site mutants organized by patterns.
Mutation
pEmpty
WT
T173A
T87A
S97A
G104N
T234A
E379N/A381T
S116A
T126A
S398A
T403A
S373A
GP subunit
GP1
GP1
GP1
GP1
GP1
GP1
GP1
GP2
GP2
GP2
GP2
% GPC/GP2
expressiona
0
100
92
28
30
55
75
93
83
85
77
88
105
% Surface
expressionb
0
100
100
94
89
104
115
102
101
152
108
83
152
% GP1/GP2
Cleavagec
0
82
77
0.4
0.8
28
82
89
81
80
88
76
92
Fid
0.02
0.08
0.69
0.02
0.02
0.20
0.20
0.30
0.78
0.60
0.80
0.73
0.91
% VLP
infectivitye
0
100
94
4.5
1.5
1.3
<1
<1
4.5
5.5
18
27
145
% pseudotype
infectivityf
0
100
75
0
0
0
0
0
15
13
53
30
160
aRelative to wt GPC/GP2 expression. Percent of permeabilized transfected cells labeled for GP2 and measured by ﬂow cytometry in two replicates. Data were analyzed using FlowJo
software. Mean values were analyzed using GraphPad software. Standard deviations for the assay fell between 0.9% and 9.2% of the mean.
bRelative to wt GPC expression. Percent of non-permeabilized transfected cells labeled for GP2 measured by ﬂow cytometry in two replicates. Data were analyzed using FlowJo
software. Mean values were analyzed using GraphPad software. Standard deviations for the assay fell between 6% and 23% of the mean.
cRelative intensity of GP2, expressed as percentage of the cleaved product GP2 versus total products GPC and GP2 observed in wt control transfected cells. Caveolin-1 was used as
loading control. Mean values were obtained by densitometry analysis of band intensities in six replicates from Western blots probed with a GP2 speciﬁc antibody, using Quantity
One software. Standard deviations ranged from 2% to 9% of the means.
dFusion index (FI), calculated using the equation FI=1−(number of cells /number of nuclei), based on the examination of four microscopic ﬁelds per mutant. Standard deviations
ranged from 5% to 23% of the means.
ePercentage of infectivity in a VLP system assay relative to wt control, as measured by CAT expression. Standard deviations ranged from 0.2% to 5% of the means.
fPercentage of infectivity in a retroviral pseudotype assay relative to wt control. Standard deviations ranged from 2% to 15% of the means.
Each box represents a different pattern of altered phenotypes.
Fig. 3. Surface glycoprotein expression. (A) Cell surface labeling in HEK 293T cells was determined by immunoﬂuorescence using an anti-GP2 speciﬁc monoclonal antibody directly
coupled to Alexa Fluor 488. Non-permeabilized cells were ﬁxed using 1% paraformaldehyde. Images were analyzed by ImageJ software. (B) Surface expression of N-glycosylation site
mutants. The expression for each mutated N-glycosylation site is expressed as a percentage of wt expression. (C) Correlation between percent cleavage and percent surface
expression. Percent cleavage versus percent surface expression is plotted for all N-glycosylation site mutants. Error bars indicate standard errors of the means.
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Fig. 4. Cell fusion assay. (A) Representative DBT cell fusion assay with N-glycosylation site mutants. Transfected DBT cells were exposed to pH 5 at 48 h post-transfection for 1 h, then
returned to neutral pH for an additional 1 h, ﬁxed with paraformaldehyde and stained with Giemsa. Syncytia are marked with an arrow. (B) Fusion index (FI) with N-glycosylation
site mutants. Cells were scored by using the FI for four representative ﬁelds, calculated as follows: FI=1−(number of cells /number of nuclei). Error bars indicate standard errors of
themeans. (D) Correlation between fusion index and percent cleavage. Fusion index versus percent cleavage is plotted for all N-glycosylation sitemutants. The cutoff, represented by
a dot line, shows no fusion when cleavage is b75%.
228 C.J. Bonhomme et al. / Virology 409 (2011) 223–233N-glycosylation site mutations S116A, T126A, T173A, S398A and T403A
impaired infectivity while the infectivity of mutant S373A was improved
All of the N-glycosylation site mutants were tested for VLP
infectivity, using previously described procedures (Lee et al., 2002;
Saunders et al., 2007). VLP infectivity was assessed by quantifying
levels of reporter gene expression in BHK cells infected with VLP and
LCMV to provide the viral trans-acting factors required for RNA
replication and expression of the minigenome (MG) RNA associated
with infectious VLP. Results for all mutants are represented in Fig. 5A
and summarized in Table 1. No VLP was detectable in the supernatant
of transfected cells for N-glycosylation mutants T87A, S97A andG104N (data not shown). As a result, no VLP infection was detected.
Despite near-wt levels of GPC expression, cell surface localization,
processing, cell fusion and detection of VLPs in the supernatant of
transfected cells, mutants T234A and E379N/A381T produced nonin-
fectious VLPs, and mutants S116A and T126A maintained only 5%
infectivity. The S398A and T403A mutants formed VLPs with 18% and
27% infectivity, respectively. These results suggest that infectious VLPs
required not only processed GPC but also N-glycosylation sites. In
contrast, mutant S373A that corresponds to the ﬁrst N-glycosylation
site in GP2 produced infectious VLPs with 145% infectivity compared
to the wt glycoprotein. Infectivity was also assessed by retrovirus
pseudotyping (Table 1). Results were similar to the results of the VLP
Fig. 5. N-glycosylation site mutant VLP infectivity. (A) The VLP infectivity for each mutation is expressed as a percent of wt VLP infectivity. Error bars indicate standard errors of the
means. (B) Correlation between percent infectivity and fusion index is plotted for all N-glycosylation site mutants. The cutoff, represented by a dot line, shows no infectivity when
fusion index is b0.6.
229C.J. Bonhomme et al. / Virology 409 (2011) 223–233infectivity assay. To address the possibility that N-glycosylation site
mutations affected VLP infectivity at viral fusion events, percent VLP
infectivity versus fusion index (FI) was plotted for all N-glycosylation
mutants (Fig. 5B). We observed no infectivity when the FI fell below
0.6. However, GP-mediated fusion alone did not guarantee particle
infectivity.
N-linked glycan at position 173 is responsible for masking epitope GP-1D
The isolates of LCMV used in our laboratory, Arm-5 and Arm-4, are
two of the ten clones plaque-puriﬁed in 1981 from a parental stock of
LCMV Armstrong (CA 1371), which were used to generated
monoclonal antibodies (Buchmeier et al., 1980, 1981). Published
data from Wright et al. (1989) described that of these ten clones, all
possessed the major neutralizing epitope A but only ﬁve reacted with
monoclonal antibodies speciﬁc for epitope GP-1D (Wright et al.,
1989). The nucleotide sequence of GP1 from Arm-5 (epitope A+D−)
and Arm-4 (epitope A+D+) revealed two variations in GP1. These
variants occurred at position 173, with a threonine in Arm-5 and an
alanine in Arm-4, and at position 252, with a leucine in Arm-5 and a
phenylalanine in Arm-4. However, the L252F variant was also found in
the WE strain of LCMV. To determine if the amino acid change at
position 173, which disrupts an N-glycosylation site, played a role in
the masking of epitope GP-1D, this N-glycosylation site in Arm-5 was
mutated and assayed for detection by immunoﬂuorescence using a
monoclonal antibody speciﬁc for epitope GP-1D (2-11-10), which is
able to recognize Arm-4 but not Arm-5 (Fig. 6). As expected, cells
infected with Arm-5 or cells transfected to express the wt GP from
Arm-5 were negative for epitope GP-1D. On the contrary, cells
infected with Arm-4 and cells transfected to express the N-
glycosylation mutation T173A in Arm-5 GP were detected by the
anti-epitope GP-1D antibody. This result demonstrated that the N-
glycan linked on the Asp of this N-glycosylation site was responsible
for the masking of the neutralizing epitope GP-1D on the Arm-5 clone.
Discussion
LCMV Arm-5 glycoprotein possesses 9 potential N-glycosylation
sites: 6 sites on GP1 and 3 sites on GP2 (Fig. 1A). Alignment of the
glycoprotein protein sequences of 28 arenaviruses indicated that
three N-glycosylation sites on GP2 were conserved in all members,
except one. On the contrary, there was high diversity in the number
and position of the N-glycosylation sites in GP1. Moreover, a similar
pattern appeared for the Old World arenaviruses. The strict
conservation of N-glycosylation sites suggested that the presence ofN-linked glycans plays an important role in protein expression,
processing, transport and cell fusion or viral infectivity.
In the present study, we conﬁrmed that all predicted N-
glycosylation sites on GP1 were used by LCMV. Similar observations
have been reported in Lassa fever virus (Eichler et al., 2006).
Moreover, the LCMV glycoprotein was able to tolerate heterologous
N-glycosylation sites inserted in GP1 or GP2. However, LCMV GP2
appeared to use only two of the three predicted N-glycosylation sites.
These were suggested in 1990 based on digestion of Arm-4 GP2 by
endoglycosidase (Wright et al., 1990). We conclude that the predicted
site at position 373 was not used. Interestingly this site is part of the
peptide GPC 370–382 recognized by the monoclonal antibody anti-
GP2 83.6, which reacted with diverse Old and New World arena-
viruses (Weber and Buchmeier, 1988). Our data also revealed that the
GP transport to the cell surface did not require proper GPC cleavage, as
conﬁrmed with the defective mutants T87A and S97A. N-glycosyla-
tions appeared to not be involved in the GPC transport to the cell
surface according to previous publications (Eichler et al., 2006; Kunz
et al., 2003). However, our assays did not distinguish between
properly and improperly formed GP complexes. As a result, the GP
transport to the cell surface was not predictive of changes in other
functions. On the contrary, a strong relationship was observed
between GPC processing, cell fusion and infectivity. This allowed the
establishment of a functional hierarchy for GPCwhere each function is
a requirement for the next: expression NGP1/GP2 cleava-
geN fusogenicityN infectivity. A defect in one function predicts defects
in subsequent GP activities, while the ability to perform one function
does not guarantee the ability to perform other downstream GP
activities. A similar hierarchy was proposed for the signal peptide of
LCMV GP (Saunders et al., 2007). This hierarchy allowed us to discuss
our N-glycosylation sites mutation by hierarchic functional pattern.
Interestingly, the unprocessed GPC has a dominant negative effect in
the fusion assay. This has already been reported for the Newcastle
disease virus (Li et al., 1998). We suppose that the unprocessed GPC is
unable to undergo the structural modiﬁcations needed to perform
fusion with host membranes. This can inhibit the fusogenicity of the
remaining processed proteins.
We observed that mutants T87A, S97A and G104N abrogated
virtually all GP functions. All induced a critical drop in GPC expression
resulting in decreased processing. These data showed that the N-
glycosylations at positions 87 and 97 were required for wt-like levels
of expression and were also necessary for processing. Moreover, the
N-glycosylation site at position 97 was conserved in all arenaviruses
(Fig. 1B) supporting the importance of this N-glycosylation site. These
mutations were also described in Lassa fever virus with similar defect
in processing (Eichler et al., 2006). The detrimental effect of adding an
Fig. 6. Detection of epitope GP-1D. DBT cells infected with either LCMV Arm-4 or Arm-5 and transfected DBT with T173A or wt were submitted to detection of the epitope GP-1D
using monoclonal antibody 2-11-10. GP2 was detected by the monoclonal antibody 83.6. Only the glycoproteins lacking the N-glycosylation site at position 173 were recognized by
the anti epitope GP-1D monoclonal antibody 2-11-10.
230 C.J. Bonhomme et al. / Virology 409 (2011) 223–233N-linked glycan close to the N-term of GP1 suggested the region near
amino acid 104 was required for expression. This decrease in
expression could be the result of an unfolded GPC protein, despite
good surface expression. Indeed, the overproduction could produce
enough GPC comparable to wt-like levels in surface expression.
The T234A mutation, despite very good expression, showed
limited capacity to induce GP-mediated cell fusion resulting in no
detectable VLP infectivity. This suggests that the last N-glycosylation
on GP1, at position 234, was required for GP-mediated fusion. The
presence of N-linked glycans has been shown to be necessary for
budding and infectivity in LCMV (Wright et al., 1990) and syncytium
formation in measles virus (Malvoisin and Wild, 1994). Since this N-
glycosylation site was conserved in 24/28 arenavirus glycoproteins,
we suppose that the N-linked glycan at position 234 plays a key role in
GP-mediated fusion. On the other hand, insertion in LCMV of a glycan
at position 379/381 otherwise present in all arenaviruses except
LCMV and Dandenong virus led to a similar defect in GP-mediated
fusion that resulted in a loss of VLP infectivity. We thereforehypothesize that modiﬁcation in this region could have an effect on
LCMV GP-mediated fusion. Due to the natural presence of this glycan
in all the arenavirus strains, except LCMV and Dandenong virus, we
believe this is speciﬁc for LCMV and possibly Dandenong virus.
The S116A and T126Amutants localized on GP1 exhibited very low
infectivity despite good expression, processing and fusion. Every
function testedwith GP alonewas comparable to the wt. This was true
with both VLP infectivity and retroviral pseudotyping assay showing
that this low infectivity was a direct consequence of N-glycosylation
mutants S116A and T126A. Moreover, puriﬁcation of VLP by
ultracentrifugation through 20% sucrose allowed us to detect GP
from VLP on Western blots for both mutants (data not shown).
However, the method was poorly reproducible and highly variable
making quantiﬁcation difﬁcult. Nevertheless, the assay conﬁrmed that
we were not isolating “naked VLPs” that lacked GP. Nevertheless, we
suppose that the level of incorporation into the VLP of these mutants
was lower than the wt GP. Similar patterns were observed for both
S398A and T403 mutants with a decrease in VLP infectivity but still
231C.J. Bonhomme et al. / Virology 409 (2011) 223–233less than 27% compared to the wt. Once again, GP alone mediated all
the functions tested so lower levels of incorporation of the N-
glycosylation mutants into VLP could explain the observed results.
Mutation T173A was designed to recreate the Arm-4 clone N-
glycosylation variation in order to conﬁrm that this N-linked glycan at
position 173 was responsible for masking of epitope GP-1D in Arm-5.
This mutant behaved like the Arm-4 clone, arguing that all functions
were similar to the wt. This suggests that the second mutation
described in the Arm-4 clone, leucine to phenylalanine at position
252, did not play a role in infectivity. In addition, our immunoﬂuo-
rescence data demonstrated a direct role for this N-glycan in the
masking of epitope GP-1D. Masking of epitope by N-glycosylation has
been shown in the case of HIV and inﬂuenza virus andmay permit the
characterization of neutralizing antibodies using an epitope-unmask-
ing procedure (Ditzel et al., 1995; Munk et al., 1992).
The ﬁrst predicted N-glycosylation site on GP2 present in all
arenaviruses was not found to be used. This point mutation was
responsible for the gain in all functions tested for GP, resulting in an
increased infectivity compared to the wt. Increases in infection
following mutation of an N-glycosylation site were described for the
HCV glycoprotein (Delgrange et al., 2007) and the foamy virus
glycoprotein (Luftenegger et al., 2005) and were responsible for a
higher infectious titer. However, in our case, the increased functions
were not linked to the presence of a glycan. This mutation presents a
perfect hyper-infectious control for testing in recombinant LCMV.
In summary, our study shows that each N-linked glycan in the
arenavirus glycoprotein is involved in GPC expression, GP-mediated
fusion or infectivity. Further studies are needed to elucidate the role of
these N-glycosylation mutants in a recombinant virus system.
Interestingly, a recent publication on pandemic strains of inﬂuenza
suggested a novel role for glycans in viral evolution and vaccine
design. This work suggested that the 1918 pandemic virus evaded
antibodies by mutating the tips of the glycoprotein to change the
presentation of glycans. Surprisingly the 2009 pandemic strain
reverted to a conﬁguration similar to that of the original 1918 strain.
This reinforces our idea that glycans are used as a cloud around the
glycoprotein to mask epitopes on the viral glycoprotein from
neutralizing antibodies. Further investigations using recombinant
LCMV N-linked glycan mutants to enhance exposure of epitopes may
facilitate vaccination against arenaviruses.
Materials and methods
Cell lines and virus
DBT murine astrocytoma cells, BHK-21 hamster kidney ﬁbroblast
and HEK 293T human embryonic kidney cells were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin–streptomycin. The
LCMV Armstrong clone 4 (Arm-4) and clone 5 (Arm-5) were used
throughout these studies (Wright et al., 1989).
Plasmids and transfections
All point mutants were made from pC–GPC–Flag (LCMV Arm53b
GPC) (Capul et al., 2007) by the use of a QuikChange PCR mutagenesis
kit (Stratagene). Mutations were conﬁrmed by sequencing. Each N-
glycosylation site mutation was made in a full-length GPC gene.
Plasmids expressing the LCMV L (pC–L), NP (pC–NP) and Z (pC–Z)
proteins and T7 RNA polymerase (pC–T7) under the control of a
modiﬁed chicken β-actin promoter, as well as minigenome (MG)
under the control of a T7 promoter, have been previously described
(Lee et al., 2002). All transfections were performed with fresh
preparations of plasmids using Lipofectamine 2000 (Invitrogen)
according to manufacturer's instructions, using 2.5 μl Lipofectamine/μg plasmid DNA. The transfection medium was replaced with fresh
medium containing 5% FBS at 5 h post-transfection.
Western blot
HEK 239 T or DBT cells were collected 48 h post-transfection in
lysis buffer (50 mM Tris–HCl pH 8, 62.5 mM ethylenediaminetetraa-
cetic acid [EDTA], 1% NP-40 and 0.4% sodium deoxycholate [DOC]).
Cell lysates were mixed with NuPAGE® LDS Sample Buffer completed
with NuPAGE® Sample Reducing Agent (Invitrogen) and boiled for
10 min. Lysates were then separated by SDS–polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes. Mem-
branes were blocked with 5% powdered milk in phosphate-buffered
saline (PBS), 0.2% Tween, for 1 h at room temperature. Incubation
with the primaries anti-GP2 monoclonal antibody 83.6 at dilution 1/
100 and Anti-Caveolin-1, clone 7C8 mouse monoclonal, at 4 μg/ml
(Upstate Cell Signaling) was performed overnight at 4 °C. Membranes
were washed with PBS Tween, probed with an anti-mouse secondary
antibody conjugated to alkaline phosphatase (Santa Cruz Biotechnol-
ogy) at dilution 1/1000 for 1 h at room temperature and washed an
additional three times. Membranes were developed by incubation
with Immun-Star Alkaline Phosphatase Substrate (Bio-Rad) then
chemiluminescence was observed with the Chemidoc™ XRS (Bio-
Rad). Densitometry analysis was performed with Quantity One
software (Bio-Rad) as follows. For each lane, the densitometry was
measured for the band corresponding to GPC, GP2 and the loading
control caveolin. The total of GPC+GP2 or GP2-only was normalized
using the loading control. The percentage of cleavage was calculated
as follow: percentage of cleavage=[(normalized density of the GP2
band) / (normalized density of the GPC+GP2 bands)]×100. As
examples, 0% cleavage means no GP2 band detected whereas 100%
means no GPC band detected.
Flow cytometry
Transfected HEK 293T or DBT cells were carefully washed with
cold PBS then blocked with 3% bovine serum albumin (BSA), 0.1% PFA
in PBS for 1 h at 4 °C. Cells were permeabilized by treating with 0.1%
Triton X-100 for 5 min at 4 °C. Incubation was performed with anti-
GP2 antibody 83.6 directly coupled to Alexa 488 at 1/100 overnight at
4 °C, then washed carefully once. Cells were then detached by
pipetting, then washed 2 more times in 5 ml round bottom tubes.
Cells were ﬁnally ﬁxed with 3.7% PFA and analyzed by ﬂow cytometry
using a FACSCalibur (BD Biosciences). Data were analyzed using
FlowJo 8.8.6 software.
Immunoﬂuorescence assay
HEK 293T or DBT cells were grown on cover slips, transfected as
described previously, then washed with cold PBS and ﬁxed with 3.7%
paraformaldehyde (PFA) for 15 min. Cells were blocked with 5% BSA
in PBS for 1 h at RT. Cells were incubated with anti-GP2 antibody 83.6
directly coupled to Alexa 488 or anti epitope GP-1D 2-11-10, at 1/100
overnight at 4 °C. Cells were visualized using a Nikon Eclipse Ti
microscope with NIS-Element AR 3.00 sp7 software.
VLP infectivity assay
HEK 293T cells were plated in 35-mm wells at 8×105 cells/well.
After 24 h, cells were 70% conﬂuent and were transfected with a mix
of pC–NP (0.4 μg), pT7–MG (0.25 μg), pC–T7 (0.5 μg), pC–L (0.4 μg),
pC–Z (0.5 μg), wt or mutant pC–GPC–Flag (0.4 μg). The amount of
total plasmid DNA was brought to 3 μg ﬁnal by empty vector. At 48 h
post-transfection, VLP-containing supernatants (2 ml) were har-
vested and clariﬁed at 2000 rpm for 5 min at 4 °C. Half of the
supernatants were used to infect fresh monolayers of BHK-21 cells.
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removed and LCMVArm-4was added at amultiplicity of infection of 3
to provide the viral trans-acting factors required for RNA replication
and expression of the MG RNA (Lee et al., 2002). After 3 h adsorption,
the inoculum was replaced by fresh media. At 48 h post infection,
BHK-21 cells were lysed and assayed for chloramphenicol acetyl-
transferase (CAT) expression.
CAT enzyme-linked immunoabsorbent assay to quantify VLP infectivity
CAT assays were done as described previously (Saunders et al.,
2007). Brieﬂy, cells were collected in PBS andwhole-cell extractswere
obtained by 3 freeze–thaw cycles. The concentration of CAT was
measured using a CAT enzyme-linked immunosorbent assay kit
(Roche Applied Science) according to the manufacturer's protocol.
DBT cell fusion assay
DBT cells were transfected with pC–GPC–Flag containing each
individual N-glycosylation mutant. At 48 h post-transfection, cells
were exposed to pH 5 buffered medium for 1 h then returned to
neutral pH for 1 h. Cells were ﬁxed with 4% PFA and stained with
Giemsa. The extent of syncytium formation was quantiﬁed using
representative images at 100× magniﬁcation. The following equation
was used to calculate the fusion index (FI): FI=[1−(number of cells /
number of nuclei)] (Saunders et al., 2007).
Production of retrovirus and percentage infectivity
HEK 293T cells at 70% conﬂuencywere cotransfected with 1.3 μg of
each plasmids pCgp, pCnBg and pC–GPC–Flag with 10 μl of
Lipofectamine 2000. Plasmid pCgp is a packaging construct that
encodes MuLV Gal-Pol (Han et al., 1998), and pCnBg is a retrovirus
vector genome carrying a nuclear β-galactosidase reporter gene (Han
et al., 1997). Determination of vector titer was performed as publish
previously (Christodoulopoulos and Cannon, 2001). At 48 h post-
transfection, the supernatant from transfected HEK 293T cells
containing the retroviruses was harvested. Serial dilutions of the
vector supernatants were prepared, and 1 ml of each dilution was
added to a freshmonolayer of cells with 8 μg/ml of Polybrene (Sigma).
The titer was determined by staining overnight with X-Gal (5-bromo-
4-chloro-3-indolyl-beta-D-galactopyranoside) at 48 h post-transduc-
tion. The titer was determined by counting blue colonies in each well,
which was normalized to wt LCMV GP and expressed as percentage of
infectivity compared to the wt.
Statistical analysis
All statistical analyses were generated using Prism 4 (GraphPad)
software.
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